The present invention relates to novel NADPH oxidase proteins, or Nox, the use thereof, the method of preparation thereof and the method for identification thereof.

The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1α (HIF-1α) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.

The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.

A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying KTRRKMDRYDKSNIL in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are obviously improved.

The disclosure relates to compositions for use in assays, the compositions comprising at least one latent fluorophore including at least one enzyme-reactive quenching group and a conjugative group; and a support connectable to the latent fluorophore by the conjugative group. The disclosure further relates to methods of measuring the presence and/or concentration of an analyte, as well as methods of measuring the relative activity of at least two enzymes.

A specific antibody for detecting the blood brain barrier early injury of cerebral ischemic stroke is characterized by specifically identifying specifically identifying DHYETDYTTGGESC in degradation fragments of an occludin protein, but not identifying the full-length occludin protein. Therefore, the antibody can be used for specifically detecting the blood brain barrier early injury of the cerebral ischemic stroke, and can eliminate the influence of the full-length occludin protein in serum on a detection result, so that the specificity and accuracy of detecting the blood brain barrier early injury of the cerebral ischemic stroke are significantly improved.

Methods and devices for testing and monitoring L-phenylalanine in biological samples are provided.

The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.

Devices and methods for sensing analytes in a solution sample are provided. The device includes a substrate, a conversion component configured to convert the analyte in the sample solution into a metabolite, and an aptamer sensor configured to measure a presence of the metabolite, the aptamer sensor located on the substrate.

The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.